



#### NOTICE OF MEETING 2025

Notice is given that the 2025 Annual General Meeting (AGM) of CSL Limited (ABN 99 051 588 348) will be held on Tuesday, 28 October 2025 at 10 a.m. (Melbourne time).

Shareholders may attend in person at the RACV City Club, Level 17, 501 Bourke Street, Melbourne 3000 or participate online at https://meetings.lumiconnect.com/300-052-251-591

#### **OUR VALUES**

Our Values, as shown on the right, are fundamental to our success - helping us to save lives, protect the health of people and earn our reputation as a trusted and reliable global leader.

#### **Patient Focus**

Make people and patients your passion

#### Integrity

Walk your talk

#### **Innovation**

Reach for the unreachable

#### **Superior Performance**

Make yourself proud

#### Collaboration

Adventure together

#### CONTENTS

Items of Business	4
Explanatory Notes	8
Important Information on	

Voting and Participation





CSL is delivering enduring patient impact around the world

+ READ MORE IN OUR **IMPACT REPORT 2025** 



20

# Invitation from the Chair

On behalf of your Board of Directors, I am pleased to invite you to the 2025 Annual General Meeting (AGM) of CSL Limited (CSL or the Company).

CSL's AGM will be held on Tuesday, 28 October 2025 at the RACV City Club, Level 17, 501 Bourke St, Melbourne 3000, starting at 10 a.m. (Melbourne time).

This meeting will be held in a hybrid format (in person and online) meaning shareholders have the option to join the meeting either at the venue or virtually. Further details about attending the meeting are set out in this notice on page 20.

Shortly after opening the AGM, I will address the meeting and then our Chief Executive Officer, Dr Paul McKenzie will review CSL's operations and performance over the year to 30 June 2025. More information about our financial and operational performance are included in our Annual Report which can be found on our website CSL.com.

We will then move through the items of business set out in this Notice of Meeting, and shareholders as a whole will have an opportunity to ask questions and make comments about the management and operations of the Company.

The AGM is an important opportunity to hear from our shareholders. We encourage shareholders to submit their written questions well in advance of the AGM by logging into <a href="www.investorvote.com.au">www.investorvote.com.au</a> and submitting questions no later than 5 p.m. (Melbourne time) Tuesday, 21 October 2025.

We will endeavour to answer as many of the frequently asked questions as practicable during the meeting.

At last year's Annual General Meeting, CSL received a 'first strike' on its Remuneration Report. While this was disappointing, the Board has taken this feedback very seriously and has consulted broadly with shareholders and other stakeholders to understand the concerns that led to the first strike. Our response to the first strike and the changes implemented to CSL's remuneration structure are set out in our 2025 Remuneration Report at page 61 of the Company's Annual Report.

In the event we receive a 'second strike' at this year's AGM on the Remuneration Report, a resolution to spill the Board will be put to shareholders. If the conditional resolution is put to the AGM, the Board unanimously recommends that shareholders vote

AGAINST the conditional resolution

#### **CSL's Board of Directors**

This year, Ms Marie McDonald and Dr Megan Clark AC will retire from the Board. Both have been highly respected, valued and hard working Board members. Ms McDonald steps down after 12 years as a Non-executive Director, and Dr Clark after 9 years as a Non-executive Director. On behalf of the Board I thank them both for their contributions and wish them well for the future.

We are pleased that Dr Brian Daniels joined the Board on 1 December 2024 as a Non-executive Director. He is a member of the Innovation and Development Committee. You can read more about Dr Daniels on page 9. Dr Daniels is standing for election to the Board of CSL at the AGM and the Board recommends Dr Daniels election as a Non-executive Director.



We will also welcome Mr Cameron Price as a Non-executive Director from 1 October 2025. He is a member of the Human Resources and Remuneration Committee and he will become the Chair of Human Resources and Remuneration Committee at the end of the 2025 AGM. You can read more about Mr Cameron Price on page 10. Mr Price is standing for election to the Board of CSL at the AGM and the Board recommends his election as a Non-executive Director.

### **Board Recommendation**

The Board recommends that shareholders vote in favour of the resolutions in Items 2, 3, and 4 and against Item 5 if it is put to the AGM.

Thank you for your continued support of CSL. I encourage you to join us at the AGM and look forward to welcoming you then.

Yours faithfully,

Brian McNamee AO Chair

### Items of Business

### 1. Financial Statements and reports

To receive and consider the Financial Statements and the reports of the Directors and Auditors for the year ended 30 June 2025.

#### 2. Election of Directors

To consider and, if thought fit, to pass the following resolutions each as an ordinary resolution:

- a) That Dr Brian Daniels, who retires as a Director in accordance with CSL's Constitution and, being eligible, be elected as a Non-executive Director.
- b) That Mr Cameron Price, who retires as a Director in accordance with CSL's Constitution and, being eligible, be elected as a Non-executive Director.

# 3. Adoption of the Remuneration Report

To consider and, if thought fit, to pass the following as a non-binding ordinary resolution:

That the Remuneration Report for the year ended 30 June 2025 as set out in the Directors' Report of the Annual Report be adopted.

### Voting exclusion applicable to Item 3

CSL will disregard any votes cast on Item 3:

- by or on behalf of a person who is a member of CSL's Key Management Personnel (KMP) named in the Remuneration Report for the year ended 30 June 2025, and their closely related parties (regardless of the capacity in which the vote is cast); or
- as proxy by a person who is a member of the KMP on the date of the AGM and their closely related parties.

However, votes will not be disregarded if they are cast as proxy for a person entitled to vote on Item 3:

- in accordance with the directions on the proxy form; or
- by the person chairing the meeting in accordance with an express authorisation in the proxy form to exercise the proxy as the chair of the meeting decides, even though Item 3 is connected with the remuneration of CSL's KMP.

The chair of the meeting intends to vote all available proxies in favour of Item 3.

# 4. Approval of a grant of Performance Share Units to the Chief Executive Officer and Managing Director, Dr Paul McKenzie

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of Performance Share Units to the Chief Executive Officer and Managing Director, Dr Paul McKenzie, as his annual long-term incentive for the year ended 30 June 2026 as set out in the Explanatory Notes to this Notice of Meeting.

### Voting exclusion applicable to Item 4

CSL will disregard any votes on Item 4:

- cast in favour of the resolution by or on behalf of Dr McKenzie or any of his associates (regardless of the capacity in which the vote is cast); and
- cast as proxy by a person who is a member of the KMP on the date of the AGM or their closely related parties.

However, votes will not be disregarded if they are cast on Item 4:

- as proxy or attorney for a person entitled to vote on the item in accordance with the directions given to the proxy or attorney to vote on the resolution in that way; or
- as proxy for a person entitled to vote on the item by the person chairing the meeting in accordance with an express authorisation to exercise the proxy as the chair of the meeting decides; or
- by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the item; and
  - the holder votes on the item in accordance with directions given by the beneficiary to the holder to vote in that way.

The chair of the meeting intends to vote all available proxies in favour of Item 4.

# **Contingent Business**

# 5. Conditional Board spill resolution

If required, to consider, and if thought fit, to pass the following resolution as an ordinary resolution:

That, subject to and conditional on at least 25% or more of the votes validly cast on the resolution in Item 3 (Adopting the Remuneration Report for the year ended 30 June 2025) being cast against that resolution:

- a) an extraordinary general meeting of the Company (the Spill Meeting) be held within 90 days of the passing of this resolution;
- all of the directors who were directors of the Company when the resolution to make the Directors' Report for the year ended 30 June 2025 was passed and who remain in office at the time of the Spill Meeting cease to hold office immediately before the end of the Spill Meeting; and
- c) resolutions to appoint persons to offices that will be vacated immediately before the end of the Spill Meeting be put to the vote of shareholders at the Spill Meeting.

Note: This is a conditional resolution and will only be put to the 2025 AGM if at least 25% of the votes validly cast on the resolution proposed in Item 3 are against that resolution.

If you do not want a Spill Meeting to take place, you should vote 'Against' Item 5. If you want a Spill Meeting to take place, you should vote 'For' Item 5.

The Board recommends that shareholders vote **AGAINST** Item 5 if it is put to the AGM.

### Voting exclusion applicable to Item 5

CSL will disregard any votes cast on Item 5:

- by or on behalf of a person who is a member of CSL's KMP named in the Remuneration Report for the year ended 30 June 2025, and their closely related parties (regardless of the capacity in which the vote is cast); or
- as proxy by a person who is a member of the KMP on the date of the AGM and their closely related parties.

However, votes will not be disregarded if they are cast as proxy for a person entitled to vote on Item 5:

- in accordance with the directions on the proxy form; or
- by the person chairing the meeting in accordance with an express authorisation in the proxy form to exercise the proxy as the chair of the meeting decides, even though Item 5 is connected with the remuneration of CSL's KMP.

In accordance with CSL's Constitution, CSL will also disregard any votes cast on Item 5 by a shareholder that is a 'significant foreign shareholder', as that term is defined in the Constitution.

The chair of the meeting intends to vote all undirected proxies against Item 5 if it is put to the meeting.

# **Explanatory Notes**

The Explanatory Notes that follow form part of the Notice of Meeting and provide important information regarding the items of business to be considered at the AGM.

#### Item 1

#### **Financial Statements and reports**

The laws in Australia require Directors to lay the annual financial report (or statements) and the reports of the Directors and the Auditor for the financial year ended 30 June 2025 before the AGM.

This item does not require a formal resolution to be put to the Meeting. However, shareholders as a whole will be given a reasonable opportunity to submit questions about, or make comments on, the reports and the management of CSL. Shareholders will also be given a reasonable opportunity to submit questions to a representative of the Company's Auditor, Deloitte, in relation to the conduct of the audit (including the independence of the Auditor), the preparation and content of the auditor's report and the accounting policies adopted by the Company.

+ READ MORE AT INVESTORS.CSL.COM/
INVESTORS/ANNUAL-REPORT

#### Item 2

#### **Election of Directors**

Dr Brian Daniels joined the Board in December 2024 and Mr Cameron Price joined the Board in October 2025 after completion of appropriate background checks. In accordance with Rule 65(c) of CSL's Constitution, they will retire at the end of the AGM, and being eligible submit themselves for election.

# Item 2(a) Election of Director



Dr Brian Daniels BS, MS, MD

Dr. Daniels received Bachelor of Science and Medical Science degrees from Massachusetts Institute of Technology and his M.D. from Washington University, St. Louis. He trained in internal medicine at New York Hospital and rheumatology/immunology at UCSF.

Dr Daniels has over 30 years of experience in clinical development, medical affairs, commercialization and biotech investing. Dr Daniels is currently a partner at 5AM Ventures, joining as a Venture Partner in 2014 and becoming a Partner in 2018.

Dr Daniels spent more than 20 years in clinical drug development, including leading the Development and Medical Affairs division at Bristol-Myers Squibb. He directed the development of numerous innovative medicines across a number of therapeutic areas including in Cardio-Vascular, Virology and Oncology.

Dr Daniels is Chairperson at Artiva Biotherapeutics and Director at Inipharm. The Board has determined that Dr Daniels is an independent Director.

In light of the skills and experience detailed above, the Board (with Dr Daniels abstaining) recommends that shareholders vote in favour of the election of Dr Daniels as a Non-executive Director of CSL.

### **Explanatory Notes**

# Item 2(b) Election of Director



Mr Cameron Price LLB(Hons), BEc

Mr Price holds a Bachelor of Laws (First Class Honours) and Bachelor of Economics from Monash University.

Mr Price has extensive experience in global investment markets, risk management, public affairs, and legal strategy and compliance. Until recently, he was General Counsel & Chief Risk Officer at the Future Fund, Australia's Sovereign Wealth Fund, which manages the global investment of more than \$300 billion of funds including the \$240 billion Future Fund and the \$24 billion Medical Research Future Fund. He held this role for 11 years.

Prior to that Mr Price was a senior commercial lawyer, partner and Board member at law firm Allens for 25 years, specialising in mergers & acquisitions, equity capital markets and corporate governance and compliance.

Mr Price is a Director on the Board of Ruyton Girls' School.

The Board has determined that Mr Price is an independent Director.

In light of the skills and experience detailed above, the Board (with Mr Price abstaining) recommends that shareholders vote in favour of the election of Mr Price as a Non-executive Director of CSL.

#### Item 3

#### Adoption of the Remuneration Report

Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is contained in the 2024/25 Annual Report and starts on page 61. You can obtain a copy of the 2024/25 Annual Report on <u>CSL.com</u> or by contacting CSL's share registrar, Computershare.

Shareholders as a whole will have a reasonable opportunity at the meeting to submit questions about or make comments on the Remuneration Report. Item 3 is required under Australian law and the vote on the adoption of the Remuneration Report is an advisory vote only and does not bind the Directors or the Company. However, the Board will take the outcome of the vote into consideration when reviewing remuneration practices and policies of the Company for future years.

The Remuneration Report includes:

- an explanation of CSL's policies in relation to the nature and amount of the remuneration of the KMP:
- a description of the relationship between CSL's remuneration policies and CSL's performance; and
- remuneration details for KMP and any associated performance conditions for the period ended 30 June 2025.

Voting restrictions apply in relation to this item and are described in the Items of Business on page 4.

Shareholders should note that while the vote on Item 3 is advisory only, if 25% or more of the votes cast on this item are 'against' adopting the Company's Remuneration Report, Item 5 (conditional Board spill meeting resolution) will be put to the meeting. The operation and consequences of the conditional Board spill meeting resolution are set out in the additional notes to Item 5 on page 19.

The Board recommends that shareholders vote in favour of adopting the Remuneration Report for the financial year ended 30 June 2025.

#### **Explanatory Notes**

#### Item 4

# Approval of a Grant of Performance Share Units to the Chief Executive Officer and Managing Director, Dr Paul McKenzie

Under the Australian Securities Exchange (**ASX**) Listing Rules, shareholder approval is required for an issue of CSL securities to Directors.

#### 4.1 Proposed Grant

It is proposed that Dr Paul McKenzie, an Executive Director of CSL and the Chief Executive Officer and Managing Director, be granted 58,360 Performance Share Units (**PSUs**) as his long-term incentive (**LTI**) for the year ended 30 June 2026. The Board believes it is in shareholders' interests to provide Dr McKenzie with an equity-based incentive to ensure there is alignment between returns for shareholders and Dr McKenzie's reward.

If approved by shareholders, the awards will be made under the CSL Limited Executive Performance and Alignment Plan (the **EPA Plan**, which is operated under the CSL Limited Performance Rights Plan), and PSUs will be granted at no cost within twelve months of the AGM

Each PSU granted under the EPA Plan is a conditional right to one fully paid ordinary share in CSL, subject to meeting the applicable service and performance conditions, including the Return on Invested Capital (**ROIC**) and Earnings per Share (**EPS**) growth (**EPSg**) performance measures described below. PSUs carry no voting or dividend entitlements.

The key terms of the 2026 grant of PSUs to Dr McKenzie are set out below:

#### Grant value

The grant value, or target opportunity, of Dr McKenzie's LTI is equivalent to 425% of Dr McKenzie's base salary of US\$1,930,883 as at 1 September 2025, being US\$8,206,253.

The grant value was converted to Australian dollars using the RBA closing exchange rate on 29 August 2025 (being A\$0.6538). For 2026, the total grant value in Australian dollars is A\$12,551,625.

# Number of PSUs to be granted

The number of PSUs to be granted to Dr McKenzie is 58,360, being the above grant value in A\$ divided by the Market Price.

The Market Price is the five day volume weighted average price at which CSL Shares were traded on the ASX up to and including 29 August 2025, being A\$215.07.

The PSUs are divided into two tranches – Tranche 1 will comprise 70% of the total number of PSUs and Tranche 2 will comprise the remaining 30%. The number of PSUs in each tranche is as follows:

- · Tranche 1: 40,852; and
- · Tranche 2: 17,508.

### 4.2 Determination of targets

Tranche 1 is subject to a ROIC performance measure and Tranche 2 is subject to an EPSg performance measure. Both performance measures will be assessed at the end of a three-year performance period (1 July 2025 to 30 June 2028).

When determining the performance hurdles the Board considered a range of factors including CSL's strategy, historical and forecast financial performance, the Board approved budget and external factors including guidance and other relevant market disclosures. Sensitivity analysis and modelling was also undertaken to test both the threshold and target values selected to create ambition and sufficient stretch, and alignment with shareholder interests.

# Performance measures

#### Tranche 1 - ROIC

At the test date, Tranche 1 of PSUs that are eligible to be tested for vesting will be subject to a performance assessment based on the growth of ROIC (in percentage points) over the 3 years from FY25 (year ended 30 June 2025) to FY28 (year ending 30 June 2028), where:

ROIC = 
$$\frac{\text{(Reported EBIT x (1 - Effective Tax Rate))}}{\text{(Average Equity + Average Net Debt)}}$$

For prior "on foot" awards, performance is assessed on the basis of average ROIC over the relevant 3 years. For the FY26 LTI grant, the timing and extent of the strategic initiatives announced on 19 August 2025 means the use of average ROIC would not appropriately represent CSL's long term ROIC objectives. As a result, for the FY26 LTI grant, the Board considers it more appropriate to determine vesting outcomes based on the improvement in ROIC from FY25 to FY28.

CSL continues to use statutory measures for the LTI.

#### Tranche 2 - EPSg

At the test date, Tranche 2 of PSUs that are eligible to be tested for vesting will be subject to an EPSg three-year compound annual growth rate performance measure, where:

EPS = CSL Reported NPAT attributable to CSL shareholders in USD

Weighted Average Number of Shares on Issue

#### **Explanatory Notes**

### Performance hurdle and vesting

#### Tranche 1 - ROIC

Full vesting will occur on achievement of target level performance, with partial (33%) vesting on achievement of threshold performance. Note that the 33% vesting is a reduction from prior years and is in response to shareholder feedback about the quantum of vesting for threshold ROIC performance.

Performance level	ROIC percentage point growth	FY28 ROIC result	Outcome
Below threshold	Less than 1.5	ROIC less than 13.0%	0% vesting
Threshold	1.5	ROIC of 13.0% (calculated to one decimal point)	33% vesting on achievement of threshold level performance
Between threshold and target	1.5 to 2.2	ROIC of between 13.0% and 13.7% (calculated to one decimal point)	Vesting on a straight-line basis between 33% and 100%
Target	2.2	ROIC of 13.7% (calculated to one decimal point)	100% vesting
Above target	Above 2.2	ROIC above 13.7%	Outcome capped at 100% – cannot exceed target

Further to the above vesting schedule, an additional gateway must be passed before vesting of Tranche 1 can occur. This gateway requires that ROIC is delivering a minimum acceptable return across the 3-year performance period. Specifically, the gateway requires that the arithmetic average of the 3 annual ROIC outcomes during the performance period exceeds CSL's internal investment hurdle rate. This rate is based on the minimum return we require on our investments to ensure we are making sound investment decisions and appropriately manage risk and clearly exceed our cost of capital. The rate applicable in the year ending 30 June 2028 will be used for the purposes of this gateway.

Performance will be measured on 1 September 2028 based on ROIC for the financial year ending 30 June 2028. The Board considers that testing performance on this basis recognises the importance of growing ROIC over the longer term.

### Performance hurdle and vesting continued

#### Tranche 2 - EPSg

Vesting will occur on achievement of target level performance, with partial vesting (50%) on achievement of threshold performance.

Performance level	Hurdles	Outcome
Below threshold	EPSg less than 9.0%	0% vesting
Threshold	EPSg of 9.0% (calculated to one decimal point)	50% vesting on achievement of threshold level performance
Between threshold and target	EPSg of between 9.0% and 10.0% (calculated to one decimal point)	Vesting on a straight-line basis between 50% and 100%
Target	EPSg of 10.0% (calculated to one decimal point)	100% vesting
Above target	EPSg above 10.0%	Outcome capped at 100% – cannot exceed target

Performance will be measured on 1 September 2028 based on the three-year compound annual growth rate of EPS over the period 1 July 2025 to 30 June 2028. The base figure is the EPS recorded in the financial year immediately prior to the grant (ended 30 June 2025) and the performance is measured by reference to the EPS recorded in the financial year immediately prior to the date of vesting (ending 30 June 2028). EPS will be adjusted to exclude the effect of any share repurchases/buybacks that have the effect of materially reducing the number of ordinary shares outstanding during the performance period. The Board considers that testing performance on this basis recognises the importance of sustained longer-term performance.

#### Tranches 1 and 2

Any PSUs that do not vest following testing of the performance hurdles at the vesting date will lapse. There will be no retesting of performance hurdles.

The Board has the absolute discretion (subject to legal and Listing Rule requirements) to adjust the ROIC or EPSg performance conditions, including the hurdles and vesting schedules. In making any adjustment, the Board may take into account any matter that it considers relevant, including matters outside of management's influence, the impact of any material acquisitions or corporate activity, one-off non-recurrent items, or a broader assessment of CSL performance outcomes.

As communicated in the 2024 Remuneration Report, a change has been made to the EPA Plan for Dr McKenzie's award. At the end of the three-year performance period, for any PSUs that vest, an additional one-year holding period will be applied to any shares held by Dr McKenzie after taking into account any shares that need to be sold to cover Dr McKenzie's tax withholding obligations.

#### **Explanatory Notes**

### 4.3 Award term

# Holding lock period

12 months from vesting (expected to be from 1 September 2028 to 31 August 2029).

# Cessation of employment

If Dr McKenzie ceases employment with CSL before the PSUs vest then, unless the Board determines otherwise, all unvested PSUs will lapse.

However, if Dr McKenzie ceases employment by retirement, redundancy, death, total or permanent disability or another 'qualifying leaver' reason as determined by the Board in its absolute discretion then, unless the Board determines otherwise, Dr McKenzie will retain a pro-rated number of PSUs based on the period elapsed from the start of the performance period to the date of cessation. Such PSUs will remain on foot subject to the original terms and conditions of the awards including award Vesting Date.

To the extent permitted by law, the Board may elect to settle any PSUs vesting by way of a cash payment (rather than ordinary shares).

If Dr McKenzie ceases employment with CSL before the end of the holding lock period for any reason, the holding lock period will continue to apply and Dr McKenzie will not be able to access the shares until the restriction is lifted.

# Clawback and malus

The terms of the award will be subject to the Board approved Company Clawback and Malus Policy and Risk Management/Reward Framework.

This policy enables the clawback or adjustment of any incentive awards which vest (or may vest), including but not limited to any gain realised from the disposal of the underlying shares, as a result of fraud, dishonesty, risk management outcomes, violation of any material law or regulation, material misstatement, omission or error in the financial statements, material violation of CSL's Code of Conduct or any other policy governing the conduct of employees or serious and wilful misconduct.

### Change of Control

In the event of a change of control of the Company, unless otherwise determined by the Board, a pro-rated number of PSUs granted, based on the time elapsed since the issue date, will be tested against the performance measures and will vest based on the extent to which the performance measures have been met.

Any shares that are subject to the holding lock period will be dealt with, so that Dr McKenzie will remain, as of the date of the determination, in a financial position in respect of the shares which is as near as possible to that which existed immediately prior to the change of control event occurring.

### 4.4 Additional information provided in accordance with ASX Listing Rule 10.15

### Why is approval being sought and what will happen if approval is not given?

ASX Listing Rule 10.14 provides that a listed company must not issue equity securities to a Director under an employee incentive scheme unless it obtains the approval of its shareholders. Dr McKenzie is a "director" for the purposes of ASX Listing Rule 10.15.1.

CSL is seeking shareholder approval for the purposes of Listing Rule 10.14 to give CSL the flexibility to issue shares to satisfy PSUs that vest and for transparency and governance reasons.

If shareholder approval is not obtained, then the Board will provide alternative remuneration to Dr McKenzie in order to appropriately remunerate and incentivise him, which will most likely be an equivalent cash amount, subject to the same performance, service and other conditions, including the holding period.

# Why are PSUs used for Dr McKenzie's LTI?

CSL uses PSUs because they create share price alignment between executives and ordinary shareholders but do not provide the executives with the full benefits of share ownership (such as dividend and voting rights) unless and until the PSUs vest and shares are allocated.

### Other Information

As the PSUs will form part of Dr McKenzie's remuneration for 2026, they will be granted at no cost and there will be no amount payable by Dr McKenzie on vesting of the PSUs.

Shares allocated on vesting of the PSUs will be subject to a one-year holding lock. At the end of the holding lock period, no further restrictions on trading (subject to CSL's Securities Dealing Policy) will be applied.

There is no loan scheme in relation to the PSUs or the shares allocated on vesting of the PSUs.

Dr McKenzie is prohibited from dealing in PSUs and hedging the share price exposure in respect of PSUs.

Dr McKenzie will be eligible to receive dividends on his shares during the holding lock period.

#### **Explanatory Notes**

### Other Information continued

Dr McKenzie is the only Director who is eligible to participate in, and receive PSUs under, the EPA Plan. The ASX Listing Rules require this Notice of Meeting to state the number of securities that have previously been issued to, and average price of securities paid by, Dr McKenzie for those securities under the EPA Plan. The EPA Plan was introduced in 2017 and since implementation 135,765 PSUs have been issued (at no cost) to Dr McKenzie under the EPA Plan in respect of prior year LTI.

ASX Listing Rule 10.15.4 requires this Notice of Meeting to include details (including the amount) of Dr McKenzie's current total remuneration. Details of Dr McKenzie's remuneration at the date of this Notice of Meeting are set out below.

Fixed remuneration (salary)	US\$1,930,883
Short-term incentive	120% of fixed remuneration at target, 240% of fixed remuneration at maximum
Long-term incentive	425% of fixed remuneration on a face value basis

Further details of Dr McKenzie's remuneration are set out in the Remuneration Report on pages 61 to 89 of the 2024/25 Annual Report.

Details of any PSUs or CSL shares issued under the EPA Plan will be published in the Company's Annual Report relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14. Any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of securities under the EPA Plan after this resolution is approved and who are not named in this Notice of Meeting will not participate until approval is obtained under that rule unless an exception under Listing Rule 10.16 applies.

Voting restrictions apply in relation to this item and are described in the Items of Business on page 5.

The Board (with Dr McKenzie abstaining) recommends that shareholders vote in favour of granting Performance Share Units to the Chief Executive Officer and Managing Director, Dr McKenzie.

### **Contingent Business – Item 5**

### **Conditional Board spill resolution**

This resolution will only be put to the AGM if at least 25% of the votes validly cast on Item 3 (the resolution to adopt the Remuneration Report) are cast against the adoption of the Remuneration Report. If less than 25% of the votes validly cast on Item 3 are against adopting the Remuneration Report at the 2025 AGM, then there will be no second strike and Item 5 will not be put to the meeting.

If put to the meeting, the conditional Board spill resolution will be considered as an ordinary resolution. If this resolution is passed and becomes effective, a special meeting of shareholders known as a "Spill Meeting" must be held within 90 days. The following Non-executive directors will cease to hold office immediately before the end of the Spill Meeting unless they are re-elected at the Spill Meeting:

- · Dr Brian McNamee:
- · Professor Andrew Cuthbertson:
- · Dr Brian Daniels;
- · Carolyn Hewson;
- · Samantha Lewis;
- · Elaine Sorg; and
- · Alison Watkins.

Although Dr Megan Clark and Ms Marie McDonald held directorships when the Board passed the resolution for the Directors' Report for financial year ended 30 June 2025, they will have retired at the close of the 2025 AGM and will not be required to stand for re-election at the Spill Meeting.

If Mr Cameron Price is elected at the 2025 AGM, he will not be required to stand for re-election at the Spill Meeting as he was not in office at the time that the Directors' Report for the financial year ended 30 June 2025 was passed.

Voting restrictions apply in relation to this item and are described in the Items of Business on page 6.

The Board recommends that shareholders vote **AGAINST** the contingent spill resolution. By order of the Board

Thead

Fiona Mead Company Secretary

17 September 2025

The Board recommends that shareholders vote **against** the contingent spill resolution.

# **Important Information**

### How to participate in person

Shareholders are invited to attend the CSL AGM in person at the RACV City Club, Level 17, 501 Bourke St Melbourne on Tuesday, 28 October 2025 at 10 a.m. (Melbourne time). Please visit the RACV City Club website for more information on getting to the venue.

### Registrations will open at 9 a.m.

The health of CSL's shareholders, employees and other meeting attendees is of paramount importance. Please do not attend the AGM in person if you feel unwell. Other restrictions and precautionary measures may also be imposed on attendance if necessary, including limiting or refusing entry to visitors and other attendees.

All shareholders are encouraged to submit written questions in advance of the meeting and to lodge a directed proxy, even if they plan to attend the meeting in person.

If it becomes necessary or appropriate to make alternative arrangements for the meeting, shareholders will be given as much notice as possible and further information will be provided on CSL's website.

# How to participate in the AGM online

You can participate online in real time using the Lumi online platform. This can be done from your computer, tablet, or mobile device with an internet connection. You can access the online platform from your device by clicking <a href="https://example.com/here/bases/bases/">https://example.com/here/bases/bases/<a>

The platform will allow shareholders to view the meeting live, vote, submit questions and make comments (verbally and in writing) in real time. Please note, to participate and vote online you will need your security holder number and postcode and must register at least 15 minutes before the meeting commences.

The AGM will also be webcast on our website CSL.com.

# By participating in the meeting online you will be able to:

- vote between the commencement of the meeting and the closure of voting as announced by the chair of the meeting;
- hear the meeting discussion and view the live webcast; and
- submit and ask questions at the appropriate time while the meeting is in progress.

To participate in the AGM online, you can log in to the meeting from your computer or mobile device by clicking <u>here</u>.

Once you have entered the URL above in your browser, you will need the following information to participate in the AGM in real time:

- (a) Your username, which is your SRN/HIN. Proxyholders will need to contact Computershare on +61 3 9415 4024 at least one hour prior to the AGM to obtain log-in details.
- (b) Your password, which is the postcode registered to your holding if you are an Australian shareholder. Overseas shareholders should refer to the AGM Online Meeting Guide for their password details.

Further information regarding participating in the AGM online, including browser requirements, is detailed in the AGM Online Meeting Guide available on <u>CSL.com</u>.

#### **Technical difficulties**

Technical difficulties may arise during the course of the AGM. The chair of the meeting has discretion as to whether and how the meeting should proceed in the event that a technical difficulty arises. In exercising their discretion, the chair of the meeting will have regard to the number of shareholders impacted and the extent to which participation in the business of the meeting is affected.

# Proxy voting and proxyholder participation

CSL encourages shareholders to submit a proxy vote online ahead of the meeting, even if you are planning to attend in person or online. Proxy votes can be lodged at www.investorvote.com.au.

Proxyholders may contact CSL's share registry, Computershare Investor Services Pty Ltd, on +61 3 9415 4024 for further information.

#### Am I entitled to vote at the AGM?

To vote at the AGM you must be a registered holder of CSL shares as at 10 a.m. (Melbourne time) on Sunday, 26 October 2025. The number of shares you hold at that time determines your voting entitlement.

Restrictions apply on the eligibility of certain people to vote on particular items of business. CSL has set out the applicable voting exclusions for the relevant item of business immediately after the proposed resolution in this Notice of Meeting.

### How will voting be conducted?

A poll will be called on each of the resolutions set out in this Notice of Meeting. A show of hands will not be conducted.

# How do I register my attendance at the meeting venue on the day of the AGM?

You must register to vote at the AGM. The registration desk will be open from 9 a.m. Melbourne time and you should arrive at least 30 minutes before the meeting commences to allow enough time to complete registration. To make the registration process quicker, please bring your proxy form to the meeting so we can scan the personalised barcode to register your attendance.

# How do I register my online attendance on the day of the AGM?

If shareholders and proxyholders wish to participate online, they must use the Lumi online platform. Online registration will open from 9 a.m. (Melbourne time) on Tuesday, 28 October 2025 and shareholders and proxyholders should login at least 15 minutes prior to the meeting. To make the registration process quicker, please have your SRN/HIN and registered postcode or country code ready.

Proxyholders will need to contact the call centre on +61 3 9415 4024 one hour before the meeting to obtain their login details.

# When and how do I lodge a proxy?

A proxy appointment (and the power of attorney or other authority under which it is signed, if any) must be received by CSL's Share Registry, no later than 10 a.m. (Melbourne time) on Sunday, 26 October 2025. See information under 'I am entitled to vote but I can't participate in the meeting in person or online – what should I do?' for further details related to appointing a proxy.

#### Important Information

Shareholders who receive their Notice of Meeting and proxy form electronically will have received an e-mail with a link to the Computershare site. You will need your SRN/HIN and your postcode to submit your proxy appointment.

Shareholders who receive hard copies of their Notices of Meeting will also receive a proxy form in the mail.

Proxies may be lodged in the following ways:

- Online: <u>www.investorvote.com.au</u> and following the instructions set out on the website.
- Mail: CSL Share Registrar Computershare Investor Services Pty Limited GPO Box 242 Melbourne, Victoria 3001

You can arrange to receive shareholder information electronically by contacting Computershare on 1800 646 882 (within Australia) or +61 3 9415 4178 (outside Australia) or at www.investorcentre.com/au.

Intermediary custodian voting: for intermediary online subscribers only (custodians) please submit your voting intentions at <a href="https://www.intermediaryonline.com">www.intermediaryonline.com</a>. If you have appointed a proxy to attend the Meeting and then you also attend the Meeting your proxy will not be revoked, unless you instruct Computershare that you would like to revoke your proxy prior to the meeting. In this case, your proxy will not be eligible to vote on those items of business.

# I have a power of attorney from a shareholder – how do I vote?

An original or certified copy of the power of attorney under which you are authorised to attend and vote at the meeting must be provided to CSL's Share Registry prior to the AGM or brought to the meeting venue (unless you or the shareholder have previously lodged this paperwork with CSL's Share Registry).

# I am a corporate shareholder – how can I participate and vote?

A body corporate that is a shareholder, or has been appointed proxy, may appoint an individual to act as its representative at the AGM. The appointment must comply with the requirements of section 250D of the Corporations Act. Evidence of the appointment, including any authority under which it has been signed must be provided to CSL's Share Registry prior to the AGM or brought to the meeting venue (unless it has previously been given to CSL or CSL's Share Registry).

# I am a representative of a corporate shareholder – how can I participate and vote?

Please ensure the requirements of section 250D of the Corporations Act have been complied with and provide evidence of your appointment, including any authority under which it is signed, CSL's Share Registry prior to the AGM or bring it to the meeting venue.

# I am entitled to vote but if I can't attend the meeting in person or online – what should I do?

Shareholders are entitled to appoint a proxy to attend and vote on your behalf. The proxy need not be a shareholder of CSL and may be an individual or a body corporate. See above for details on how to lodge a proxy.

More details are set out below to assist you with setting up your proxy vote properly.

# How do I ensure I appoint a valid proxy?

If you are entitled to attend and vote at the meeting, you may appoint a proxy, and up to two proxies where you are entitled to cast two or more votes.

Each proxy will have the right to vote on a poll and to speak at the meeting.

Where two proxies are appointed, you may specify the proportion or number of votes that each proxy may exercise. If you appoint two proxies and do not specify the proportion, each proxy may exercise half your votes. Fractions of votes are disregarded.

If you wish to indicate how your proxy should vote, please mark the appropriate boxes on the proxy form. If you do not direct a proxy on how to vote on an item of business or should any resolution other than those specified in this Notice of Meeting be proposed at the meeting, your proxy may vote or abstain from voting on that resolution as they see fit (subject to any applicable voting exclusions).

If you instruct your proxy to abstain from voting on an item of business, they are directed to not vote on a poll and the shares, subject of the proxy appointment, are not counted in calculating the required majority.

If you submit your proxy form but do not nominate the identity of your proxy, then CSL will deem the chair of the meeting as your proxy to vote on your behalf.

If you submit your proxy form with a direction on how to vote and your nominated proxy does not participate in the meeting or does not vote on the resolution in accordance with your directions, the chair of the meeting will act in place of your nominated proxy and vote in accordance with your instructions (subject to any voting restrictions).

# What if my proxy is a KMP of CSL or a closely related party of the KMP?

You can appoint a member of CSL's KMP (which includes each of the Directors and the Executive KMP) and their closely related parties (such as close family members and any controlled companies) as your proxy. However, unless the chair of the meeting is your proxy, members of CSL's KMP and their closely related parties will not be able to vote as proxy on Items 3, 4 and 5 unless you direct them how to vote by marking the voting boxes on the proxy form for those items. Dr McKenzie and his associates will not be able to vote your proxy in favour of item 4 unless you direct them how to vote. The chair of the meeting may vote any undirected proxies as they decide, even though Items 3, 4 and 5 are in connection with KMP remuneration.

# Can I appoint the chair of the meeting as my proxy?

Yes, you can appoint the chair of the meeting as your proxy.

If you appoint the chair of the meeting as your proxy, or the chair of the meeting is appointed as your proxy by default, and you do not mark the voting boxes on the proxy form for Items 3, 4 and 5, by completing and submitting the proxy form you are expressly authorising the chair of the meeting to exercise your proxy as he sees fit in relation to those resolutions even though Items 3, 4 and 5 are connected with the remuneration of CSL's KMP.

The chair of the meeting intends to vote all available proxies in favour of Items 2 to 4 and against Item 5.

#### Important Information

# Can I ask questions at the meeting?

Shareholders may ask questions at the meeting, whether they attend in person or participate online. To ask a question online during the AGM (verbally or in writing), shareholders must use the Lumi online platform. A reasonable opportunity will be given to shareholders as a whole at the AGM to ask questions about, or make comments on, all items of business and the management of CSL.

You are encouraged to submit written questions relating to CSL and the business of the AGM in advance of the meeting. Shareholders may also submit questions to CSL's Auditor in advance of the meeting on the content of the Auditor's report or the conduct of its audit of CSL's Financial Report for the year ended 30 June 2025. The Auditor is not obliged to provide written answers.

Shareholders can submit their questions in advance of the meeting at www.investorvote.com.au.

Questions must be received by no later than 5 p.m. (Melbourne time) on Tuesday, 21 October 2025.

The chair of the meeting will endeavour to address the more frequently raised themes during the course of the meeting. However, there may not be sufficient time available at the meeting to address all of the questions raised. Please note that individual responses will not be sent to shareholders.

CSL produces a range of publications that can be viewed or downloaded at <u>CSL.com</u>. You can elect to receive a paper copy of the Annual Report by contacting CSL's Share Registrar.

CSL confirms that this document complies with the notice of meeting content requirements set out in the Listing Rules. ASX has provided no objection to this document under Listing Rule 15.1.4 based on this confirmation.

IF UNDELIVERABLE PLEASE RETURN TO: GPO Box 2848 Melbourne VIC 3001 Australia POSTAGE PAID AUSTRALIA



CSL

MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030











Phone:

1800 646 882 (within Australia) +61 3 9415 4178 (outside Australia)



Online:

www.investorcentre.com/contact

CSL

MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030

# **CSL Limited Annual General Meeting**

The CSL Limited (the **Company**) Annual General Meeting will be held on Tuesday, 28 October 2025 at 10 a.m. (Melbourne time). You are encouraged to participate in the meeting using the following options:



# MAKE YOUR VOTE COUNT

To lodge a proxy, access the Notice of Meeting and other meeting documentation visit www.investorvote.com.au and use the below information:



Control Number: 999999 SRN/HIN: I9999999999

PIN: 99999

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

For your proxy appointment to be effective it must be received by 10 a.m. (Melbourne time) on Sunday, 26 October 2025.



# ATTENDING THE MEETING VIRTUALLY

To watch the webcast, ask questions and vote on the day of the meeting, please visit https://meetings.lumiconnect.com/300-052-251-591

For instructions refer to the online user guide which can be located at https://investors.csl.com/investors/shareholder-information/agm



# ATTENDING THE MEETING IN PERSON

The meeting will be held at the RACV City Club, Level 17, 501 Bourke Street, Melbourne 3000.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.



**CSL LIMITED** ABN 99 051 588 348

CSL

MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030

# Need assistance?



#### Phone:

1800 646 882 (within Australia) +61 3 9415 4178 (outside Australia)



#### Online

www.investorcentre.com/contact



# YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by 10 a.m. (Melbourne time) on Sunday, 26 October 2025.

# **Proxy Form**

### How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

### APPOINTMENT OF PROXY

**Voting 100% of your holding:** Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

**Voting a portion of your holding:** Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

**Appointing a second proxy:** You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

# SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

**Joint Holding:** Where the holding is in more than one name, all of the securityholders should sign

**Power of Attorney:** If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

**Companies:** Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

# PARTICIPATING IN THE MEETING

### Corporate Representative

If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms".

### **Proxy Revocation**

If you have appointed a proxy to attend the Meeting and then you also attend the Meeting your proxy will not be revoked, unless you instruct Computershare that you would like to revoke the proxy. In this case, your proxy will not be eligible to vote on those items of business

# **Lodge your Proxy Form:**



#### Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is



Control Number: 999999 SRN/HIN: 19999999999

PIN: 99999

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

# By Mail:

Computershare Investor Services Pty Limited GPO Box 242 Melbourne VIC 3001 Australia

# By Fax:

1800 783 447 within Australia or +61 3 9473 2555 outside Australia



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

MR SAM SAMPLE FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Change of address. If incorrect,
mark this box and make the
correction in the space to the left.
Securityholders sponsored by a
broker (reference number
commences with 'X') should advise
your broker of any changes.



I 999999999

Provy Form

Please mark X to indicate your directions

Step 1	Appoint a	Proxy to Vote on Your	Behalf			XX
I/We bei	ng a member/s of CSI	Limited hereby appoint				
	ne Chairman f the Meeting		you	ASE NOTE: I have selected ting. Do not in	the Chairma	n of the
act genee the exter Bourke S of that m Chairma Meeting a on Items or indirect Importar	rally at the meeting on an permitted by law, as a street, Melbourne 3000 peeting.  In authorised to exercias my/our proxy (or the 3, 4 and 5 (except wheeltly with the remunerationt Note: If the Chairma	y/our behalf and to vote in accordance proxy sees fit) at the Annual Gener nd online on Tuesday, 28 October 20 se undirected proxies on remuneral Chairman becomes my/our proxy by the I/we have indicated a different voting of a member of key management p	body corporate is named, the Chairman of ce with the following directions (or if no directions (or if no directions) and the following directions (or if no directions) and the following time) and at any section related resolutions: Where I/we have default), I/we expressly authorise the Chair in gintention in step 2) even though Items 3, ersonnel, which includes the Chairman.	the Meeting ctions have RACV City adjournme e appointed man to exer 4 and 5 are	g, as my/our been given Club, Leve nt or postpo the Chairm cise my/our connected	proxy to , and to I 17, 50 nement an of the proxy directly
Step 2	Items of I		mark the <b>Abstain</b> box for an item, you are directi ur votes will not be counted in computing the requ			n your
				For	Against	Abstai
Item 2a	Election of Director -	r Brian Daniels				
Item 2b	Election of Director -	Ir Cameron Price				
Item 3	Adoption of the Rem	neration Report				
Item 3	·	·	f Executive Officer and Managing Director,			
Item 4	Approval of a grant o Dr Paul McKenzie  onal resolution - Pleas	Performance Share Units to the Chie	dered at the meeting if the conditions			
Item 4	Approval of a grant o Dr Paul McKenzie  onal resolution - Pleas	Performance Share Units to the Chie note that Item 5 will only be consi g are satisfied. The Board recomn	dered at the meeting if the conditions			
Item 4  Condition outlined  Item 5  The Chairman on any resident Step 3	Approval of a grant of Dr Paul McKenzie  Ponal resolution - Please in the Notice of Meet  Conditional Board sp  irman of the Meeting in n of the Meeting intendesolution, in which case	note that Item 5 will only be consigure satisfied. The Board recommon resolution  ends to vote undirected proxies in favor to vote against. In exceptional circuman ASX announcement will be made.	dered at the meeting if the conditions	btion of Item		
Item 4  Condition outlined  Item 5  The Chairman on any resident Step 3	Approval of a grant of Dr Paul McKenzie  conal resolution - Please in the Notice of Meet  Conditional Board sp  irman of the Meeting in of the Meeting intendesolution, in which case  Signature	Performance Share Units to the Chie note that Item 5 will only be consi g are satisfied. The Board recomn resolution  ends to vote undirected proxies in fav to vote against. In exceptional circun an ASX announcement will be made.  of Securityholder(s) 7	dered at the meeting if the conditions nends you vote Against Item 5.  our of each item of business with the except natances, the Chairman of the meeting may his section must be completed.	btion of Item		





Mobile Number

**Email Address** 



CSLRM

MR RETURN SAMPLE 123 SAMPLE STREET SAMPLE SUBURB SAMPLETOWN VIC 3030

Dear Securityholder,

We have been trying to contact you in connection with your securityholding in CSL Limited. Unfortunately, our correspondence has been returned to us marked "Unknown at the current address". For security reasons we have flagged this against your securityholding which will exclude you from future mailings, other than notices of meeting.

Please note if you have previously elected to receive a hard copy Annual Report (including the financial report, directors' report and auditor's report) the dispatch of that report to you has been suspended but will be resumed on receipt of instructions from you to do so.

We value you as a securityholder and request that you supply your current address so that we can keep you informed about our Company. Where the correspondence has been returned to us in error we request that you advise us of this so that we may correct our records.

You are requested to include the following;

- > Securityholder Reference Number (SRN);
- > ASX trading code;
- > Name of company in which security is held;
- > Old address; and
- > New address.

Please ensure that the notification is signed by all holders and forwarded to our Share Registry at:

Computershare Investor Services Pty Limited GPO Box 2975 Melbourne Victoria 3001 Australia

Note: If your holding is sponsored within the CHESS environment you need to advise your sponsoring participant (in most cases this would be your broker) of your change of address so that your records with CHESS are also updated.

Yours sincerely

**CSL Limited** 

# Online Meeting Guide

CSL Limited AGM 28 October 2025, 10:00 AEDT

# Attending the meeting virtually

Those attending online will be able to view a live webcast of the meeting. Shareholders and Proxyholders can ask questions and submit votes in real time.



To participate online, visit <a href="https://meetings.lumiconnect.com/300-052-251-591">https://meetings.lumiconnect.com/300-052-251-591</a> on your smartphone, tablet or computer.

You will need the latest versions of Chrome, Safari, Edge or Firefox. Please ensure your browser is compatible.

To log in, you may require the following information:

# Meeting ID: 300-052-251-591

Australian residents SRN / HIN

(on your proxy form)

Postcode

(postcode of your registered address)

Overseas residents

SRN / HIN

(on your proxy form)

**Country Code** 

(three-character country code) e.g. New Zealand - NZL; United Kingdom - GBR; United States of America - USA; Canada - CAN

A full list of country codes can be found at the end of this guide.

# **Appointed Proxies**

To receive your unique username and password, please contact Computershare on +61 3 9415 4024.

#### Guests

To register as a guest, you will need to enter your name and email address.

# Registering for the meeting

To participate in the meeting, follow the direct link at the top of the page.

Alternatively, visit

meetings.lumiconnect.com and enter the unique 12-digit Meeting ID, provided above.




To proceed into the meeting, you will need to read and accept the Terms and Conditions and select if you are a Securityholder/Proxy or a Guest. Note that only Securityholders and Proxies can vote and ask questions in the meeting.



To register as a Shareholder, enter your SRN or HIN and Postcode or Country Code and press Sign in.

To register as a Proxyholder, you will need your username and password as provided by Computershare. In the 'SRN or HIN' field enter your username and in the 'Postcode or Country Code' field enter your password and press Sign in.



# To register as a Guest,

enter your name and other requested details and press Continue.

$\leftarrow$	
CSL	
CSL AGM 2025	
First Name *	
Last Name *	
Email *	
Having trouble logging in? v	
	Continue

# Watching the meeting

On a desktop/laptop device, you will see the home tab on the left, which displays the meeting title and instructions. The webcast will appear automatically on the right. Press play and ensure your device is not muted.



You can watch the webcast full screen, by selecting the full screen icon.



To reduce the webcast to its original size, select the minimise icon.




On a mobile device, select the Broadcast icon at the bottom of the screen to open the webcast. Press play and ensure your device is not muted.

During the meeting, mobile users can minimise the webcast at any time by selecting one of the other icons in the menu bar.

You will still be able to hear the meeting while the broadcast is minimised. Selecting the Broadcast icon again will reopen the webcast.







# Voting

When the Chair declares the poll open:

- A voting icon will appear on screen and the meeting resolutions will be displayed.
- To vote, select one of the voting options. Your response will be highlighted.
- To change your vote, simply select a different option to override.

There is no need to press a submit or send button. Your vote is automatically counted. Votes may be changed up to the time the Chair closes the poll.






# **Text Questions**


To ask a written question, tap on the messaging icon , type your question in the box at the top of the screen and press the send button.

Confirmation that your message has been received will appear.




Questions sent via the Lumi platform may be moderated before being sent to the Chair. This is to avoid repetition and remove any inappropriate language.

A copy of your sent questions, along with any written responses, can be viewed by selecting "MY MESSAGES".




# **Audio Questions**

If you would like to ask a verbal question, click the 'Request to Speak' button at the top right corner of the broadcast window.



The audio questions interface will now display.
Confirm your details, click 'Submit Request' and follow the instructions on screen to connect.

You will hear the meeting while you wait to ask your question.



# Country Codes - Computershare

For overseas shareholders, select your country code from the list below and enter it into the password field.

<b>ABW</b>	Aruba	DOM	Dominican Republic	LAO	Lao Pdr	QAT	Qatar
AFG	Afghanistan	DZA	Algeria	LBN	Lebanon	REU	Reunion
AGO	Angola	ECU	Ecuador	LBR	Liberia	ROU	Romania Federation
AIA	Anguilla	EGY	Egypt	LBY	Libyan Arab Jamahiriya	RUS	Russia
ALA	Aland Islands	ERI	Eritrea	LCA	St Lucia	RWA	Rwanda
ALB	Albania	ESH	Western Sahara	LIE	Liechtenstein	SAU	Saudi Arabia
AND	Andorra	ESP	Spain	LKA	Sri Lanka	SDN	Sudan
ANT	Netherlands Antilles	EST	Estonia	LSO	Kingdom of Lesotho	SEN	Senegal
ARE	United Arab Emirates	ETH	Ethiopia	LTU	Lithuania	SGP	Singapore
ARG	Argentina	FIN	Finland	LUX	Luxembourg	SGS	Sth Georgia & Sandwich Isl
ARM	Armenia	FJI	Fiji	LVA	Latvia	SHN	St Helena
ASM	American Samoa	FLK	Falkland Islands (Malvinas)	MAC	Macao	SJM	Svalbard & Jan Mayen
ATA	Antarctica	FRA	France	MAF	St Martin	SLB	Soloman Islands
ATF	French Southern	FRO	Faroe Islands	MAR	Morocco	SCG	Serbia & Outlying
ATG	Antigua & Barbuda	FSM	Micronesia	MCO	Monaco	SLE	Sierra Leone
AUS AUT	Australia Austria	GAB GBR	Gabon	MDA MDG	Republic Of Moldova	SLV SMR	El Salvador San Marino
AZE	Azerbaijan	GEO	United Kingdom	MDV	Madagascar Maldives	SOM	Somalia
BDI	Burundi	GGY	Georgia Guernsey	MEX	Mexico	SPM	St Pierre and Miqueion
BEL	Belgium	GHA	Ghana	MHL	Marshall Islands	SRB	Serbia
BEN	Benin	GIB	Gibraltar	MKD	Macedonia Former Yugoslav Rep	STP	Sao Tome and Principle
BFA	Burkina Faso	GIN	Guinea	MLI	Mali	SUR	Suriname
BGD	Bangladesh	GLP	Guadeloupe	MLT	Malta	SVK	Slovakia
BGR	Bulgaria	GMB	Gambia	MMR	Myanmar	SVN	Slovenia
BHR	Bahrain	GNB	Guinea-Bissau	MNE	Montenegro	SWE	Sweden
BHS	Bahamas	GNQ	Equatorial Guinea	MNG	Mongolia	SWZ	Swaziland
BIH	Bosnia & Herzegovina	GRC	Greece	MNP	Northern Mariana Islands	SYC	Seychelles
BLM	St Barthelemy	GRD	Grenada	MOZ	Mozambique	SYR	Syrian Arab Republic
BLR	Belarus	GRL	Greenland	MRT	Mauritania	TCA	Turks & Caicos
BLZ	Belize	GTM	Guatemala	MSR	Montserra	TCD	Chad
BMU	Bermuda	GUF	French Guiana	MTQ	Martinique	TGO	Congo
BOL	Bolivia	GUM	Guam	MUS	Mauritius	THA	Thailand
BRA	Brazil	GUY	Guyana	MWI	Malawi	TJK	Tajikistan
BRB	Barbados	HKG	Hong Kong	MYS	Malaysia	TKL	Tokelau
BRN	Brunei Darussalam	HMD	Heard & McDonald Islands	MYT	Mayotte	TKM	Turkmenistan
BTN	Bhutan	HND	Honduras	NAM	Namibia	TLS	East Timor Republic
BUR	Burma	HRV	Croatia	NCL	New Caledonia	TMP	East Timor
BVT	Bouvet Island	HTI	Haiti	NER	Niger	TON	Tonga
BWA	Botswana	HUN	Hungary	NFK	Norfolk Island	TTO	Trinidad & Tobago
CAF	Central African Republic	IDN	Indonesia	NGA	Nigeri	TUN	Tunisia
CAN	Canada	IMN	Isle Of Man	NIC	Nicaragua	TUR	Turkey
CCK	Cocos (Keeling) Islands	IND	India	NIU	Niue	TUV	Tuvalu
CHE	Switzerland	IOT	British Indian Ocean Territory		Netherlands	TWN	Taiwan
CHL	Chile	IRL		NOR	Norway	TZA	Tanzania
CHN	China	IRN	Iran Islamic Republic of	NPL	Nepal	UGA	Uganda
CIV	Cote D'ivoire	IRQ	Iraq	NRU	Nauru	UKR	Ukraine
CMR	Cameroon	ISL	Iceland	NZL	New Zealand	UMI	United States Minor Outlying
COD	Democratic Republic of Congo	ISM	British Isles	OMN	Oman	URY	Uruguay
COK	Cook Islands	ISR	Israel	PAK	Pakistan	USA UZE	United States of America
COL	Colombia	ITA	Italy	PAN PCN	Panama Pitcairn Islands	VNM	Uzbekistan
CPV	Comoros Cape Verde	JAM JEY	Jamaica Jersey	PER	Peru Peru	VIVIVI	Vietnam Vanuatu
CRI	Costa Rica	JOR	Jordan	PHL	Philippines	WLF	Wallis & Fortuna
CUB	Cuba	JPN	Japan	PLW	Palau	WSM	Samoa
CYM	Cayman Islands	KAZ	Kazakhstan	PNG	Papua New Guinea	YEM	Yemen
CYP	Cyprus	KEN	Kenya	POL	Poland	YMD	Yemen Democratic
CXR	Christmas Island	KGZ	Kyrgyzstan	PRI	Puerto Rico	YUG	Yugoslavia Socialist Fed Rep
CZE	Czech Republic	KHM	Cambodia	PRK	North Korea	ZAF	South Africa
DEU	Germany	KIR	Kiribati	PRT	Portugal	ZAR	Zaire
DJI	Djibouti	KNA	St Kitts And Nevis	PRY	Paraguay	ZMB	Zambia
DMA	Dominica	KOR	South Korea	PSE	Palestinian Territory	ZIM	Zimbabwe
DNK	Denmark	KWT	Kuwait	PYF	French Polynesia		
					-		